Novartis Sues To Block Generic Reclast, Zometa Drugs

Law360, New York (February 22, 2013, 1:58 PM EST) -- Novartis Pharmaceuticals Corp. filed a lawsuit Wednesday in New Jersey federal court seeking to bar more than a dozen drugmakers from making generic versions of its osteoporosis drug Reclast and oncology drug Zometa.

Novartis is seeking to prevent drugmakers such as Actavis LLC, Apotex Inc., Sun Pharmaceuticals Industries Inc., Wockhardt USA LLC and others from producing zoledronic acid, the active ingredient in Reclast and Zometa, which they purportedly intend to launch on or soon after March 2 — the day the exclusivity on Novartis' three patents...
To view the full article, register now.